Skip to main content
    D

    DiaMedica Therapeutics Inc (DMAC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.33
    -0.46 (-5.23%)

    Market Cap: $474.29M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    DiaMedica Therapeutics Inc (DMAC) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    DiaMedica Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$32.77M, operating cash flow was -$29.06M and free cash flow was -$29.10M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$11.31M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $34.40M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0-100.0%N/AN/AN/A
    Dec 2018$500.00KN/A100.0%-1352.2%-1146.8%
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$0$500.00K$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$0$2.21K
    Gross profit$0$0$0$0$0$0$0$500.00K$0-$2.21K
    Research and development$24.61M$19.06M$13.11M$7.84M$8.77M$8.21M$7.90M$4.52M$3.21M$1.76M
    Operating income-$34.40M-$26.68M-$21.27M-$14.00M-$13.65M-$12.70M-$11.59M-$6.76M-$4.52M-$2.48M
    Net income-$32.77M-$24.44M-$19.38M-$13.68M-$13.59M-$12.29M-$10.65M-$5.73M-$4.26M-$2.22M
    EBITDA-$33.64M-$25.72M-$20.53M-$13.63M-$13.38M-$12.25M-$10.67M-$5.64M-$4.26M-$2.15M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0-$28.00K$0$0$0$13.80M$0$0$0$30.84M
    Gross profit$0$0$0-$14.00K$0$0$0-$11.00K$0$0$0-$8.00K
    Operating income-$11.62M-$10.50M-$10.48M-$9.21M-$9.03M-$8.01M-$8.14M-$8.42M-$6.88M-$5.64M-$5.74M-$5.85M
    Net income-$11.31M-$10.14M-$10.04M-$8.74M-$8.62M-$7.70M-$7.71M-$7.90M-$6.27M-$5.12M-$5.15M-$5.16M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $112.00K by $15.54M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$61.37M$46.34M$54.16M$34.40M$45.55M$28.09M$9.05M$18.34M$1.80M$1.87M
    Current assets$60.63M$44.61M$53.67M$33.84M$45.44M$27.92M$8.84M$17.97M$1.49M$1.85M
    Cash and equivalents$15.65M$3.02M$4.54M$4.73M$4.71M$7.41M$3.88M$16.82M$1.35M$1.74M
    Total liabilities$5.26M$5.63M$3.10M$2.57M$1.53M$2.08M$1.44M$1.31M$1.00M$626.97K
    Short-term debt$112.00K$103.00K$83.00K$69.00K$49.00K$65.00K$60.00K$5.00K$0$200.46K
    Shareholder equity$56.11M$40.72M$51.06M$31.83M$44.02M$26.01M$7.62M$17.02M$799.00K$1.25M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$36.15M$45.00M$53.08M$61.37M$57.05M$31.47M$38.83M$46.34M$52.52M$56.79M$49.26M$54.16M
    Total liabilities$7.49M$6.66M$5.84M$5.26M$5.42M$4.30M$4.88M$5.63M$4.56M$3.38M$2.91M$3.10M
    Cash and equivalents$6.80M$5.13M$4.87M$15.65M$3.33M$4.11M$2.59M$3.02M$4.13M$14.07M$2.10M$4.54M
    Shareholder equity$28.66M$38.34M$47.23M$56.11M$51.62M$27.17M$33.95M$40.72M$47.96M$53.41M$46.35M$51.06M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$29.06M-$22.08M-$18.73M-$11.51M-$12.25M-$9.19M-$9.10M-$5.70M-$3.90M-$3.02M
    Capital expenditures$40.00K$25.00K$24.00K$81.00K$22.00K$47.00K$2.00K$50.00K$22.00K$6.89K
    Free cash flow-$29.10M-$22.10M-$18.75M-$11.59M-$12.27M-$9.23M-$9.10M-$5.75M-$3.92M-$3.03M
    Share repurchases$400.00K$0N/AN/AN/AN/AN/AN/AN/AN/A
    Investing cash flow-$2.19M$8.56M-$18.30M$11.54M-$20.54M-$16.13M-$3.91M-$50.00K-$22.00K-$6.89K
    Financing cash flow$43.88M$11.99M$36.84M-$6.00K$30.09M$28.84M$70.00K$21.22M$3.54M$4.59M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.83M-$8.11M-$9.08M-$7.76M-$6.55M-$7.60M-$7.15M-$6.43M-$4.47M-$4.52M-$6.65M-$3.81M
    Capital expenditures$10.00K$3.00K$8.00K$6.00K$16.00K$6.00K$12.00K$7.00K$9.00KN/A$9.00K$3.00K
    Free cash flow-$8.84M-$8.12M-$9.09M-$7.77M-$6.57M-$7.60M-$7.16M-$6.44M-$4.48MN/A-$6.66M-$3.81M
    Last 12 quarters

    Frequently Asked Questions About DMAC

    What is DiaMedica Therapeutics' annual revenue?

    DiaMedica Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is DiaMedica Therapeutics profitable?

    No. DiaMedica Therapeutics reported net income of -$32.77M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does DMAC generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$29.06M minus capital expenditures of $40.00K produced free cash flow of -$29.10M.

    How much debt does DiaMedica Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $112.00K and cash and equivalents of $15.65M.